Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus

New England Journal of Medicine

Volumn 335, Issue 18, 1996, Pages 1350-1356

  Kovacs, Joseph A ^a,d   Vogel, Susan ^a   Albert, Jeffrey M ^a   Falloon, Judith ^a   Davey Jr , Richard T ^a   Walker, Robert E ^a   Polis, Michael A ^a   Spooner, Katherine ^a   Metcalf, Julia A ^a   Baseler, Michael ^b   Fyfe, Gwendolyn ^c   Lane, H Clifford ^a   Dewar, Robin J ^b   Masur, Henry ^d  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SAIC FREDERICK INC   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; ANTIVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; RECOMBINANT INTERLEUKIN 2; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV; HIV CORE PROTEIN P24; HIV INFECTIONS; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0013610170     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199610313351803     Document Type: Article

References (24)

1. Emery S, Lane HC. Immune-based therapies in HIV infection: recent developments. AIDS 1996;10:Suppl A:S159-S163.
2. Stein DS, Timpone JG, Gradon JD, Kagan JM, Schnittman SM. Immune-based therapeutics: scientific rationale and the promising approaches to the treatment of the human immunodeficiency virus-infected individual. Clin Infect Dis 1993;17:749-71.
3. Lederman MM. Host-directed and immune-based therapies for human immunodeficiency virus infection. Ann Intern Med 1995;122:218-22.
4. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
5. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995;333:1528-33.
6. Massari F, Staszewski S, Berry P, et al. A double-blind, randomized trial of indinavir (MK-639) alone or with zidovudine vs. zidovudine alone in zidovudine naive patients. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Fran cisco, September 17-20, 1995. Washington, D.C.: American Society for Microbiology, 1995:LB-6. abstract.
7. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HlV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996; 173:321-9.
8. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988;240:1169-76.
9. Schwartz DH, Skowron G, Merigan TC. Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J Acquir Immune Defic Syndr 1991;4:11-23.
10. Teppler H, Kaplan G, Smith KA, Montana AL, Meyn P, Cohn ZA. Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin-2 in patients with human immunodeficiency virus type 1 infection. J Exp Med 1993;177:483-92.
11. Teppler H, Kaplan G, Smith K, et al. Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection. J Infect Dis 1993;167:291-8.
12. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-9.
13. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis of HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
14. Phair J, Muñoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990;322:161-5.
15. Lane HC, Masur H, Gelmann EP, et al. Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. Am J Med 1985;78.417-22.
16. Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 1989;111:223-31.
17. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human im munodeficiency virus infection: a preliminary study. N Engl J Med 1995; 332:567-75.
18. 1994 Revised guidelines for the performance of CD4+ T-cell determinations in persons with human immunodeficiency virus (HIV) infections. MMWR Morb Mortal Wkly Rep 1994;43(RR-3):1-21.
19. Urdea MS, Wilber JC, Yeghiazarian T, et al. Direct and quantitative detection of HIV-1 RNA in human plasma with a branched DNA signal amplification assay. AIDS 1993;7:Suppl 2:S11-S14.
20. Dewar RL, Highbarger HC, Sarmiento MD, et al. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis 1994;170:1172-9.
21. Vasudevachari MB, Salzman NP, Woll DR, et al. Clinical utility of an enhanced human immunodeficiency virus type 1 p24 antigen capture assay. J Clin Immunol 1993;13:185-92.
22. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990;300:230-5.
23. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71.
24. Falloon J, Owen C, Kovacs J, Leavitt R, Metcalf J, Lane HC. MK-639 (Merck HIV protease inhibitor) with interleukin-2 in HIV. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17-20, 1995. Washington, D.C.: American Society for Microbiology, 1995:236. abstract.